Prophylactic ibuprofen administration during pelvic irradiation

John A. Stryker, Laurence Demers, Rodrigue Mortel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Thirty-five patients who were to begin pelvic irradiation for malignant disease were randomized to receive ibuprofen 400 mg P.O. q.i.d. during their radiotherapy or standard therapy for radiation-induced gastroin testinal symptoms. Seventeen of 19 patients in the ibuprofen group completed the protocol. There was no significant difference in the daily stool frequency between the ibuprofen and control patients during the 5-6 week course of pelvic irradiation; the incidence and severity of diarrhea was the same. There was no significant difference in the incidence of nausea reported by the patients but the severity of nausea was less in the ibuprofen group; none of the 17 patients in the ibuprofen group reported vomiting at any time, whereas, 27% of the patients in the control group reported vomiting. The difference was statistically significant (p<0.05). The data suggest that prophylactic ibuprofen administration may be beneficial in reducing the severity of nausea and preventing radiation-induced vomiting in patients who receive pelvic irradiation.

Original languageEnglish (US)
Pages (from-to)2049-2052
Number of pages4
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume5
Issue number11-12
DOIs
StatePublished - Jan 1 1979

Fingerprint

Ibuprofen
vomiting
nausea
irradiation
Nausea
Vomiting
Radiotherapy
incidence
Incidence
radiation
radiation therapy
Diarrhea
therapy
Radiation
Control Groups

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Stryker, John A. ; Demers, Laurence ; Mortel, Rodrigue. / Prophylactic ibuprofen administration during pelvic irradiation. In: International Journal of Radiation Oncology, Biology, Physics. 1979 ; Vol. 5, No. 11-12. pp. 2049-2052.
@article{ea733c5962014fa2a4593516e3ef34b0,
title = "Prophylactic ibuprofen administration during pelvic irradiation",
abstract = "Thirty-five patients who were to begin pelvic irradiation for malignant disease were randomized to receive ibuprofen 400 mg P.O. q.i.d. during their radiotherapy or standard therapy for radiation-induced gastroin testinal symptoms. Seventeen of 19 patients in the ibuprofen group completed the protocol. There was no significant difference in the daily stool frequency between the ibuprofen and control patients during the 5-6 week course of pelvic irradiation; the incidence and severity of diarrhea was the same. There was no significant difference in the incidence of nausea reported by the patients but the severity of nausea was less in the ibuprofen group; none of the 17 patients in the ibuprofen group reported vomiting at any time, whereas, 27{\%} of the patients in the control group reported vomiting. The difference was statistically significant (p<0.05). The data suggest that prophylactic ibuprofen administration may be beneficial in reducing the severity of nausea and preventing radiation-induced vomiting in patients who receive pelvic irradiation.",
author = "Stryker, {John A.} and Laurence Demers and Rodrigue Mortel",
year = "1979",
month = "1",
day = "1",
doi = "10.1016/0360-3016(79)90958-1",
language = "English (US)",
volume = "5",
pages = "2049--2052",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "11-12",

}

Prophylactic ibuprofen administration during pelvic irradiation. / Stryker, John A.; Demers, Laurence; Mortel, Rodrigue.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 5, No. 11-12, 01.01.1979, p. 2049-2052.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prophylactic ibuprofen administration during pelvic irradiation

AU - Stryker, John A.

AU - Demers, Laurence

AU - Mortel, Rodrigue

PY - 1979/1/1

Y1 - 1979/1/1

N2 - Thirty-five patients who were to begin pelvic irradiation for malignant disease were randomized to receive ibuprofen 400 mg P.O. q.i.d. during their radiotherapy or standard therapy for radiation-induced gastroin testinal symptoms. Seventeen of 19 patients in the ibuprofen group completed the protocol. There was no significant difference in the daily stool frequency between the ibuprofen and control patients during the 5-6 week course of pelvic irradiation; the incidence and severity of diarrhea was the same. There was no significant difference in the incidence of nausea reported by the patients but the severity of nausea was less in the ibuprofen group; none of the 17 patients in the ibuprofen group reported vomiting at any time, whereas, 27% of the patients in the control group reported vomiting. The difference was statistically significant (p<0.05). The data suggest that prophylactic ibuprofen administration may be beneficial in reducing the severity of nausea and preventing radiation-induced vomiting in patients who receive pelvic irradiation.

AB - Thirty-five patients who were to begin pelvic irradiation for malignant disease were randomized to receive ibuprofen 400 mg P.O. q.i.d. during their radiotherapy or standard therapy for radiation-induced gastroin testinal symptoms. Seventeen of 19 patients in the ibuprofen group completed the protocol. There was no significant difference in the daily stool frequency between the ibuprofen and control patients during the 5-6 week course of pelvic irradiation; the incidence and severity of diarrhea was the same. There was no significant difference in the incidence of nausea reported by the patients but the severity of nausea was less in the ibuprofen group; none of the 17 patients in the ibuprofen group reported vomiting at any time, whereas, 27% of the patients in the control group reported vomiting. The difference was statistically significant (p<0.05). The data suggest that prophylactic ibuprofen administration may be beneficial in reducing the severity of nausea and preventing radiation-induced vomiting in patients who receive pelvic irradiation.

UR - http://www.scopus.com/inward/record.url?scp=0018607026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018607026&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(79)90958-1

DO - 10.1016/0360-3016(79)90958-1

M3 - Article

C2 - 544584

AN - SCOPUS:0018607026

VL - 5

SP - 2049

EP - 2052

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 11-12

ER -